Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose, Effects and Characteristics of Pilocarpine

This study has been completed.
Information provided by:
Wills Eye Identifier:
First received: December 5, 2008
Last updated: December 8, 2008
Last verified: December 2008

The purpose of this investigation, in which pilocarpine was given in repeated doses, was to evaluate: Part I - the effects of different concentrations of pilocarpine hydrochloride on intraocular pressure. Part II -the effects on intraocular pressure of glaucomatous patients to pilocarpine 2% when given once, twice and four daily. In addition, we studied various attributes of the eye which may serve as indicators of responsiveness of individual patients to pilocarpine.

Condition Intervention Phase
Open-Angle Glaucoma
Drug: Pilocarpine Concentration
Drug: Pilocarpine Frequency
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dose, Effects and Characteristics of Pilocarpine

Resource links provided by NLM:

Further study details as provided by Wills Eye:

Primary Outcome Measures:
  • Intraocular Pressure [ Time Frame: 25 days ] [ Designated as safety issue: Yes ]

Enrollment: 37
Study Start Date: August 1978
Study Completion Date: December 1979
Primary Completion Date: August 1979 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pilocarpine Concentration
Varying concentration 0.5 to 8% - 22 patients were examined regarding: visual acuity, iris color, pupil size, chamber angle, C/D ratio, visual field (VF), coefficient of aqueous outflow and Goldmann tonometry. After a one month washout period, pilocarpine was used 4 times daily, in concentrations from 0.5 to 8%. The amount of IOP change was compared with various clinical findings
Drug: Pilocarpine Concentration
Varying concentration 0.5 to 8%
Experimental: Pilocarpine Frequency
Varying frequency, once to four times daily - 15 patients were included in a crossover study: IOP was checked daily for 3 days and for 9 hours on fourth day. Pilocarpine was started on day 5 once daily OD and BID OS; on day 9 once daily OD and QID OS; on day 12 QID OD and once daily OS; on day 16 once daily OD and QID OS; and on day 19 QID OD and once daily OS. No medications were used on days 23-25. IOP was measured on days 4, 8, 11, 15, 18, 22 and 25.
Drug: Pilocarpine Frequency
1 to 4 times daily


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Primary open-angle glaucoma
  • Primary open-angle glaucoma suspect
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00803803

United States, Pennsylvania
Wills Eye Glaucoma Service
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Wills Eye
Principal Investigator: George L Spaeth, MD Wills Eye Glaucoma Service
  More Information

No publications provided

Responsible Party: George L. Spaeth, M.D., Wills Glaucoma Service Identifier: NCT00803803     History of Changes
Other Study ID Numbers: 08-914E
Study First Received: December 5, 2008
Last Updated: December 8, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Wills Eye:
Primary open-angle glaucoma
Primary open-angle glaucoma suspect

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Eye Diseases
Ocular Hypertension
Autonomic Agents
Cholinergic Agents
Cholinergic Agonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Agonists
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 25, 2014